Abeona Therapeutics Inc (ABEO) USD0.01
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is EB-101, an autologous, engineered cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB). Its development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with unmet medical needs. The Company’s next generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility produced EB-101 for the pivotal Phase III VIITAL study and is capable of clinical and potential commercial production of AAV-based gene therapies. EB-101 is an autologous, engineered cell therapy in which a functioning COL7A1 gene is inserted into a patient’s own skin cells (keratinocytes) using a retrovirus.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.